Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients
Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)-based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self...
Uloženo v:
| Vydáno v: | Blood Ročník 113; číslo 8; s. 1651 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
19.02.2009
|
| Témata: | |
| ISSN: | 1528-0020, 1528-0020 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)-based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy. |
|---|---|
| AbstractList | Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)-based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy.Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)-based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy. Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)-based immunity in tumor murine models. Our group has recently demonstrated in preclinical models that the infusion of genetically modified lymphocytes (GMLs) expressing the self/tumor antigen TRP-2 is able to elicit functional TRP-2-specific effectors with antitumor activity by targeting DCs in vivo. Here we have analyzed vaccine- and tumor-specific immune responses of 10 melanoma patients treated with autologous GMLs expressing the cancer germline gene MAGE-A3. Three of 10 patients treated with MAGE-A3-GML showed an increase of circulating anti-MAGE-A3 T cells, and developed skin delayed-type hypersensitivity to MAGE-A3. Interestingly, in 2 of these patients, with progressive and measurable tumors at study entry, anti-MAGE-A3 T cells were detected not only in the blood but also within tumors resected after vaccination. These results demonstrate that the infusion of MAGE-A3-GML elicits antitumor T cells, which are capable of trafficking to inflamed tissues and of infiltrating tumors. Clinical studies on a larger group of patients are needed to evaluate the clinical efficacy of such a strategy. |
| Author | Fontana, Raffaella Bordignon, Claudio Maggioni, Daniela Ciceri, Fabio Mukenge, Sylvain Coulie, Pierre G Doglioni, Claudio Bregni, Marco Raccosta, Laura Russo, Vincenzo Cipponi, Arcadi Traversari, Catia Colau, Didier Rainelli, Cristina Lunghi, Francesca |
| Author_xml | – sequence: 1 givenname: Raffaella surname: Fontana fullname: Fontana, Raffaella organization: Cancer Gene Therapy Unit, Cancer Immunotherapy and Gene Therapy Program, Department of Oncology, Scientific Institute San Raffaele, Milan, Italy – sequence: 2 givenname: Marco surname: Bregni fullname: Bregni, Marco – sequence: 3 givenname: Arcadi surname: Cipponi fullname: Cipponi, Arcadi – sequence: 4 givenname: Laura surname: Raccosta fullname: Raccosta, Laura – sequence: 5 givenname: Cristina surname: Rainelli fullname: Rainelli, Cristina – sequence: 6 givenname: Daniela surname: Maggioni fullname: Maggioni, Daniela – sequence: 7 givenname: Francesca surname: Lunghi fullname: Lunghi, Francesca – sequence: 8 givenname: Fabio surname: Ciceri fullname: Ciceri, Fabio – sequence: 9 givenname: Sylvain surname: Mukenge fullname: Mukenge, Sylvain – sequence: 10 givenname: Claudio surname: Doglioni fullname: Doglioni, Claudio – sequence: 11 givenname: Didier surname: Colau fullname: Colau, Didier – sequence: 12 givenname: Pierre G surname: Coulie fullname: Coulie, Pierre G – sequence: 13 givenname: Claudio surname: Bordignon fullname: Bordignon, Claudio – sequence: 14 givenname: Catia surname: Traversari fullname: Traversari, Catia – sequence: 15 givenname: Vincenzo surname: Russo fullname: Russo, Vincenzo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19074732$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1KxDAUhYOM6MzoG4hk5a56m6ZpuxyG8QcUXeh6SNMbJ5ImtUnBvoWPbJlRcHUuh--cA3dBZs47JOQihes0LdlNbb1vEgZQJlAkqSiFEEdknuZsMoDB7N99ShYhfACkPGP5CTlNKyh4kbE5-X7B3nQ77KWl-0Zqx7bbeTVGDPQdHUajpLUjbX1jtMGGRk_xq-sxBBp3SANafROH1vdUumimCH1a3W2SVUaNawaFe_sAmLYdHNIp23kXpgHjqJJOYU87GQ26GM7IsZY24PmvLsnb7eZ1fZ88Pt89rFePicoqiAlyKXjDFatVWRSAihd5VdZM61zoEmRdl6DrquA1pHmmJaiGc6mFVGXeZEqyJbk69Ha9_xwwxG1rgkJrpUM_hK0QVVYAiAm8_AWHusVm2_Wmlf24_fsh-wEEmXrw |
| CitedBy_id | crossref_primary_10_1158_0008_5472_CAN_12_1656 crossref_primary_10_1093_oncolo_oyad078 crossref_primary_10_1111_j_1755_148X_2009_00634_x crossref_primary_10_1182_blood_2010_07_294520 crossref_primary_10_3109_08820139_2012_664225 crossref_primary_10_1007_s00262_011_1009_3 crossref_primary_10_1212_NXI_0000000000000276 crossref_primary_10_1038_bcj_2016_38 crossref_primary_10_1097_PPO_0b013e3181eb33a6 crossref_primary_10_3892_mco_2023_2704 crossref_primary_10_2217_imt_13_62 crossref_primary_10_1016_j_jdermsci_2016_06_009 crossref_primary_10_1002_ijc_25571 crossref_primary_10_1039_C9NR01434A crossref_primary_10_1097_CORR_0000000000000767 crossref_primary_10_1016_j_leukres_2009_11_028 crossref_primary_10_1016_j_molmed_2011_12_003 crossref_primary_10_1016_j_jos_2023_07_016 crossref_primary_10_1302_0301_620X_104B1_BJJ_2021_0874_R1 crossref_primary_10_1586_era_09_139 crossref_primary_10_1089_hum_2011_153 crossref_primary_10_1016_j_copbio_2011_03_001 crossref_primary_10_1155_2011_417403 crossref_primary_10_3389_fcell_2019_00068 crossref_primary_10_3390_cancers12030590 crossref_primary_10_1002_ijc_27939 crossref_primary_10_1200_JCO_2011_40_0887 crossref_primary_10_1097_CJI_0b013e3181ad4071 crossref_primary_10_1007_s00262_010_0948_4 crossref_primary_10_4103_ijd_IJD_323_20 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2008-07-168666 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 19074732 |
| Genre | Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 9M8 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFFNX AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW C1A CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N4W N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ VXZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c390t-e4a64d4c2bc8770ec47598b2ff56f80abb80fb974b0153fa0cd44af6ac85d3ca2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 44 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000263566100007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Nov 09 13:46:01 EST 2025 Wed Feb 19 02:29:31 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c390t-e4a64d4c2bc8770ec47598b2ff56f80abb80fb974b0153fa0cd44af6ac85d3ca2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2008-07-168666 |
| PMID | 19074732 |
| PQID | 66937006 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_66937006 pubmed_primary_19074732 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-02-19 |
| PublicationDateYYYYMMDD | 2009-02-19 |
| PublicationDate_xml | – month: 02 year: 2009 text: 2009-02-19 day: 19 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2009 |
| SSID | ssj0014325 |
| Score | 2.1448252 |
| Snippet | Dendritic cell (DC) targeting in vivo has recently been shown to confer strong and protective cytotoxic T lymphocyte (CTL)-based immunity in tumor murine... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1651 |
| SubjectTerms | Adoptive Transfer Animals Antigens, Neoplasm - genetics Antigens, Neoplasm - immunology Cancer Vaccines - administration & dosage Cancer Vaccines - adverse effects Cell Line, Tumor Chlorocebus aethiops COS Cells Genetic Therapy - methods Humans Hypersensitivity, Delayed - immunology Melanoma - immunology Melanoma - pathology Melanoma - therapy Neoplasm Proteins - genetics Neoplasm Proteins - immunology Neoplasm Staging Pilot Projects Skin Neoplasms - immunology Skin Neoplasms - pathology Skin Neoplasms - therapy T-Lymphocytes - cytology T-Lymphocytes - physiology T-Lymphocytes - transplantation Thymidine Kinase - genetics Thymidine Kinase - immunology Transfection |
| Title | Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19074732 https://www.proquest.com/docview/66937006 |
| Volume | 113 |
| WOSCitedRecordID | wos000263566100007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Ji9swFH5MO90uXTJdpqsOpTcRxZJlGQolHWbaQxNyaCG3oBUMiT1NMsPkX_Qn90my6aXQQ8EYY2zL9vt4-vRWgPd2UiobnEbtV1qKCk9Qw7SmRc2M44ggZpOkv1XzuVou68URfBxyYWJY5aATk6J2nY028rGUOJEiRD5d_qSxZ1T0rfYNNG7BMUciEwO6quUfH4LgqeUqTlCKRlbUJ84hoR7noPDs-q_oRCrZV0n8K8VMU83Fo_97ycfwsKeYZJox8QSOfDuCk2mLy-vNgXwgKegzWdNHcPfzcHT_bGj9NoJ7s97jfgK_FgjRVHpgTdL3kPUBAdDZA3JUgujLSZDrA9l0rglIaMm-I_4mxdcSZJdk59dhvL_adFuCUozFP8ls-uWcTjlpWofISqfzBU3MVvFkmwN3cYCmJTbickv6ArC7p_Dj4vz72Vfad3GgltdsT73QUjhhC2NVVTFvY4VBZYoQShkU08YoFgwuawwyEx40s04IHaS2qnTc6uIZ3G671r8AguRPlqWzstSFwK12-DxfGuWF5ZKZU3g3iGWFfyy6PnTru6vdahDMKTzPkl1d5mIeq0m0DlS8ePnPe1_Bg-xKKuikfg3HAfWDfwN37PW-2W3fJvDhfr6Y_QYVeecA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Peripheral+blood+lymphocytes+genetically+modified+to+express+the+self%2Ftumor+antigen+MAGE-A3+induce+antitumor+immune+responses+in+cancer+patients&rft.jtitle=Blood&rft.au=Fontana%2C+Raffaella&rft.au=Bregni%2C+Marco&rft.au=Cipponi%2C+Arcadi&rft.au=Raccosta%2C+Laura&rft.date=2009-02-19&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=113&rft.issue=8&rft.spage=1651&rft_id=info:doi/10.1182%2Fblood-2008-07-168666&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |